#

 *August 2018 Enquiries: Chris Pockett, Head of Communications +44 (0)1453 524133*

**Renishaw’s neurolocate 2D module makes frameless robotic neurosurgery more accessible**

**A new frameless patient registration module for the** [*neuromate*](http://www.renishaw.com/en/neuromate-robotic-system-for-stereotactic-neurosurgery--10712?utm_source=neurolocate%20campaign&utm_medium=press%20release&utm_campaign=product%20promotion%20n)® **surgical robot, the** [*neurolocate*](http://www.renishaw.com/en/neurolocate-registration-module--37008?utm_source=Neurolocate%20campaign&utm_medium=Press%20release&utm_campaign=Product%20promotion)**™**2D module, **has obtained a CE mark. Global engineering company Renishaw will now offer the *neurolocate* 2D module to hospitals across Europe to help save time and costs by realising the benefits of intraoperative imaging.**

The new ***neurolocate*** 2D module builds on Renishaw’s ***neurolocate*** 3D module, which offers the same functionality but requires an intraoperative flat panel CT system, such as the Medtronic O-Arm™. Instead, the new module requires just two X-rays to register patient position against the robot, reducing the need for costly equipment and also reducing radiation exposure.

**The *neuromate* stereotactic robot can be used for a range of functional neurosurgical procedures, including electrode implantation for deep brain stimulation and** stereoelectroencephalography (SEEG). It also has applications in biopsy, neuroendoscopy and research.

Renishaw’s ***neurolocate*** modules allow the surgeon to accurately determine the position of the patient relative to the ***neuromate*** robot. The modules allow the patient to be brought directly into theatre on the day of surgery, saving time and money for the hospital and reducing procedure time for the patient.

“The *neurolocate* 2D module is another example of how Renishaw is working to improve the surgical workflow, reduce procedure time and cut operating costs,” said Paul Fielder, Technical Manager at Renishaw’s Neurological Products Division. “The new module can work with pre-existing imaging systems already in a hospital, reducing equipment cost. For the patient, it can mean less time under anaesthesia and reduced radiation dosage.”

For more information on Renishaw’s neurological products, visit [www.renishaw.com/neuro](http://www.renishaw.com/en/neurosurgical-products-and-systems--6332?utm_source=StoneJunction&utm_medium=Hard+news&utm_campaign=REM117).

Ends 333 words

Notes to editors

UK-based Renishaw is a world leading engineering technologies company, supplying products used for applications as diverse as jet engine and wind turbine manufacture, through to dentistry and brain surgery. It has over 4,500 employees located in the 36 countries where it has wholly owned subsidiary operations.

For the year ended June 2018 Renishaw recorded sales of £611.5 million of which 95% was due to exports. The company’s largest markets are China, the USA, Germany and Japan.

Throughout its history Renishaw has made a significant commitment to research and development, with historically between 13 and 18% of annual sales invested in R&D and engineering. The majority of this R&D and manufacturing of the company’s products is carried out in the UK.

The Company’s success has been recognised with numerous international awards, including eighteen Queen’s Awards recognising achievements in technology, export and innovation.

Further information at [www.renishaw.com](http://www.renishaw.com)